आईएसएसएन: 2376-0354
Ikechukwu R Ogbu, Chinedu Ngwudike, Andrey Manov*, Alfred Danielian and Shadi N Daoud
Background: The ethnic differences in cardiovascular outcomes with sodium glucose contransporter2 (SGLT2) inhibitors and glucagon- like peptide-1 (GLP-1)receptor agonists in patients with type 2 diabetes (T2DM), Cardiovascular risk factors for atherosclerotic cardiovascular disease like age above 50, HTN, hyperlipidaemia, smoking, Family history of early atherosclerotic cardiovascular disease like age above 50, HTN, hyperlipidaemia, smoking, Family history of early atherosclerotic cardiovascular disease or established atherosclerotic cardiovascular disease and heart failure with reduced ejection fraction are not well established.
We conducted the current study to evaluate the effects of both class of drugs on the major adverse cardiovascular events related to diabetes Mellitus type 2- (MACE)-non- fatal stroke or non- fatal MI or cardiovascular death as well as heart failure related to the race, ethnicity and gender.